当前位置: X-MOL 学术Endocr. Relat. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CGM for insulinoma screening: a prospective and observational case-control study.
Endocrine-Related Cancer ( IF 4.1 ) Pub Date : 2021-05-01 , DOI: 10.1530/erc-20-0447
Jingyuan Ma 1 , Xinyu Huang 2 , Jungong Zhao 3 , Jingyi Lu 1 , Wei Lu 1 , Yuqian Bao 1 , Jian Zhou 1 , Junfeng Han 1
Affiliation  

Insulin release index (IRI) based on 72-h fasting test has been used for the definitive diagnosis of insulinoma; however, hospitalization and subsequent costs contribute to the disadvantage of IRI. Therefore, a simple and cost-effective screening procedure for the diagnosis of insulinoma for outpatients are crucially needed. Continuous glucose monitoring (CGM) has been widely used for monitoring high level of glucose in diabetic patients. The aim of the study is to determine the potential contribution or implementation of CGM in the screening of the insulinoma. We performed a single-center prospective study with the demographics and laboratory data including 28 patients with the pathological diagnosis of insulinoma and 25 patients with functional hypoglycemia as control group. The analysis showed that areas under the receiver operating characteristic (ROC) curve of coefficient of variation (CV) was 0.914. The CV cutoff point was 19% with the Youden 62.1%, the corresponding sensitivity and specificity were 82.1 and 80%, respectively. In patients with CV greater than the median, more than 60% of insulinomas were located in the head of the pancreas; most Ki-67 values were more than 2% and when compared with the group with CV smaller than the median, the average tumor size was 2.7 times larger. In conclusion, CGM can be used as a valuable tool in not only monitoring high glucose levels in diabetic patients but also identifying the etiology of insulinoma. CV greater than 19% can be highly effective for the screening of insulinoma in outpatients.

中文翻译:

用于胰岛素瘤筛查的 CGM:一项前瞻性和观察性病例对照研究。

基于 72 小时空腹试验的胰岛素释放指数 (IRI) 已被用于明确诊断胰岛素瘤;然而,住院和随后的费用导致了 IRI 的劣势。因此,迫切需要一种简单且具有成本效益的筛查程序来诊断门诊患者的胰岛素瘤。连续血糖监测 (CGM) 已广泛用于监测糖尿病患者的高血糖水平。该研究的目的是确定 CGM 在胰岛素瘤筛查中的潜在贡献或实施。我们使用人口统计学和实验室数据进行了一项单中心前瞻性研究,包括 28 名病理诊断为胰岛素瘤的患者和 25 名功能性低血糖患者作为对照组。分析表明,变异系数(CV)的受试者工作特征(ROC)曲线下面积为0.914。CV 截止点为 19%,Youden 为 62.1%,相应的敏感性和特异性分别为 82.1 和 80%。在 CV 大于中位数的患者中,超过 60% 的胰岛素瘤位于胰头;大多数 Ki-67 值超过 2%,与 CV 小于中位数的组相比,平均肿瘤大小大 2.7 倍。总之,CGM 可以作为一种有价值的工具,不仅可以监测糖尿病患者的高血糖水平,还可以识别胰岛素瘤的病因。CV大于19%对门诊胰岛素瘤筛查非常有效。CV 截止点为 19%,Youden 为 62.1%,相应的敏感性和特异性分别为 82.1 和 80%。在 CV 大于中位数的患者中,超过 60% 的胰岛素瘤位于胰头;大多数 Ki-67 值超过 2%,与 CV 小于中位数的组相比,平均肿瘤大小大 2.7 倍。总之,CGM 可以作为一种有价值的工具,不仅可以监测糖尿病患者的高血糖水平,还可以识别胰岛素瘤的病因。CV大于19%对门诊胰岛素瘤筛查非常有效。CV 截止点为 19%,Youden 为 62.1%,相应的敏感性和特异性分别为 82.1 和 80%。在 CV 大于中位数的患者中,超过 60% 的胰岛素瘤位于胰头;大多数 Ki-67 值超过 2%,与 CV 小于中位数的组相比,平均肿瘤大小大 2.7 倍。总之,CGM 可以作为一种有价值的工具,不仅可以监测糖尿病患者的高血糖水平,还可以识别胰岛素瘤的病因。CV大于19%对门诊胰岛素瘤筛查非常有效。超过 60% 的胰岛素瘤位于胰头;大多数 Ki-67 值超过 2%,与 CV 小于中位数的组相比,平均肿瘤大小大 2.7 倍。总之,CGM 可以作为一种有价值的工具,不仅可以监测糖尿病患者的高血糖水平,还可以识别胰岛素瘤的病因。CV大于19%对门诊胰岛素瘤筛查非常有效。超过 60% 的胰岛素瘤位于胰头;大多数 Ki-67 值超过 2%,与 CV 小于中位数的组相比,平均肿瘤大小大 2.7 倍。总之,CGM 可以作为一种有价值的工具,不仅可以监测糖尿病患者的高血糖水平,还可以识别胰岛素瘤的病因。CV大于19%对门诊胰岛素瘤筛查非常有效。
更新日期:2021-05-01
down
wechat
bug